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Aim: To develop biocompatible and bioresorbable negatively charged calcium 
phosphate nanoparticles (CaP-NPs) as an innovative therapeutic system for the 
delivery of bioactive molecules to the heart. Materials & methods: CaP-NPs were 
synthesized via a straightforward one-pot biomineralization-inspired protocol 
employing citrate as a stabilizing agent and regulator of crystal growth. CaP-NPs 
were administered to cardiac cells in vitro and effects of treatments were assessed. 
CaP-NPs were administered in vivo and delivery of microRNAs was evaluated. Results: 
CaP-NPs efficiently internalized into cardiomyocytes without promoting toxicity 
or interfering with any functional properties. CaP-NPs successfully encapsulated 
synthetic microRNAs, which were efficiently delivered into cardiac cells in vitro and 
in vivo. Conclusion: CaP-NPs are a safe and efficient drug-delivery system for potential 
therapeutic treatments of polarized cells such as cardiomyocytes.
First draft submitted: 18 August 2015; Accepted for publication: 3 February 2016; 
Published online: 16 March 2016
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Cardiovascular disease (CVD) is a world-
wide growing problem that afflicts close to 
1% of the population and causes 17.3 mil-
lion annual premature deaths [1]. Causes 
include ischemic, toxic, genetic, postinflam-
matory and structural defects, overall result-
ing in a mortality of ∼50% within 5 years 
from diagnosis [2]. Clinical management of 
CVDs has improved during the last decades, 
but despite significant advancements, these 
pathologies still lead to a poor quality of life 
and reduced longevity. Moreover, the prog-
nosis has been described as more malignant 
than cancer. Altogether, this entails the criti-
cal need to further understand the mecha-
nisms underlying CVDs, to identify inno-
vative therapeutic compounds as well as to 
develop more efficient and safe drug-delivery 
systems. MicroRNAs (miRNAs; miRs) are 
small regulatory RNA molecules shown to 
be disease-specific biomarkers and key regu-
lators of cardiac dysfunction [3,4]. In line 
with this, significant effort has been put into 
developing new therapeutic tools designated 
to correct levels of miRNAs found to be dys-
regulated in CVDs [5]. Modified antisense 
oligonucleotides such as 2–O-methyl-mod-
ified ones, antagomirs and locked nucleic 
acids have been largely applied for therapeutic 
knockdown of miRNA levels both in in vitro 
and in vivo models of CVDs [3]. On the other 
hand, approaches aimed at increasing the 
in vivo levels of miRNAs are still not optimal 
and require drastic improvements and new 
solutions. In fact, current miRNA mimics in 
terms of in vivo delivery, stabilization, effi-
cacy of overexpression and cell targeting have 
resulted so far to be inadequate, with use of 
miRNA-expressing adeno-associated viruses 
(AAV) as the only alternative strategy [6,7]. 
However, the long-term miRNA expression 
associated with AAV technology drastically 
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limits any therapeutic approach that requires short-
term and/or interval drug  administration.
Nanoparticle (NP) delivery platforms hold great 
promise to overcome such limitations, providing an 
alternative strategy for more efficient, controlled and 
safe drug-delivery approaches. In fact, NPs potentially 
bind and deliver a large plethora of agents such as con-
ventional drugs and more recently, nucleotides [8–10]. 
Additionally, NPs can offer a substantial protection of 
the payload against immediate diffusion from or deg-
radation in the bloodstream and at the injury site, thus 
enabling controlled drug release and sustained thera-
peutic stimulus [10]. However, while largely investigated 
in the cancer field, the development and use of efficient 
NPs for the treatment of CVDs is still in its infancy. In 
fact, to the best of our knowledge, only liposomes, NPs 
based on synthetic polymers or silica and micelles have 
been investigated so far for the delivery of various thera-
peutic molecules to myocardial cells [11–15]. However, in 
many cases, their use is drastically limited due to the 
lack of biocompatibility, reduced or very slow biode-
gradability [16], uncontrolled drug release in the blood-
stream, poor encapsulation efficacy and poor stability 
during storage [17]. Additionally, optimization of the 
synthesis of cardiac-compatible NPs requires improved 
colloidal stability, and specific size, shape and surface 
charge [18]. In line with this, we recently demonstrated 
that polystyrene latex NPs are less toxic for cardiac cells 
when generated with a negative surface charge, which is 
compatible with the intrinsic charge of well-polarized 
excitable cells (i.e., cardiomyocytes) and facilitates the 
formation of life-compatible nanopores and cellular 
internalization of NPs [19]. However, the slow dissolu-
tion and cell accumulation of polystyrene latex restricts 
the use of these NPs for therapeutic approaches. In 
summary, there is still a strong need for the identifica-
tion of new formulations based on biocompatible and 
biodegradable negatively charged NPs to overcome the 
limitations of NPs currently used for CVD treatment.
The aim of the present study was the generation of 
innovative and effective negatively charged calcium 
phosphate nanoparticles (CaP-NPs) for the delivery 
of novel therapeutic drugs (i.e., miRNAs) into cardiac 
tissue. To this end, a simple and straightforward one-
pot mineralization synthesis protocol using citrate as 
stabilizing agent has been adopted. The biocompatibil-
ity and the mechanism of internalization of CaP-NPs 
in cardiac cells were obtained and the proof of concept 
for the ability of CaP-NPs to deliver miRNAs in vivo 
into cardiac tissue was provided.
Material & methods
Synthesis of calcium phosphate nanoparticles
Functional CaP-NPs were generated according to a 
quick and simple protocol. Briefly, two aqueous solu-
tions of CaCl
2
 (10–50 mM) + Na
3
Cit (40–200 mM) 
and Na
2
HPO
4
 (12–60 mM) were mixed (1:1 v/v, 5 ml 
total) and the pH was adjusted to 8.5, adding NaOH 
aqueous solution. The mixed solution was kept in a 
water bath at 37°C for different times ranging from 
5 to 60 min. When drug conjugation was performed, 
aqueous solution of synthetic unmodified and unpro-
tected miRNA duplexes (1–10 μg/ml, IBA, Germany) 
was added to the above mixed solution. To remove 
unreacted reagents, the CaP-NP suspension was washed 
three-times by centrifugation or dialyzed for 6 h across 
a cellulose dialysis membrane with a cut-off of 3500 Da 
and immersed in 400 ml Milli-Q water. The suspension 
was recovered and stored in a fridge at 4°C. The amount 
of CaP was evaluated by freeze-drying the sample sus-
pensions and weighting the inorganic residual. The final 
concentration of aqueous CaP suspension ranged from 
60 to 300 μg/ml as a function of reagent concentration.
Characterization of CaP-NPs & CaP-NP-miRs
Size distribution and surface charge of CaP-NPs were 
evaluated by dynamic light scattering (DLS) and 
ζ-potential, respectively. CaP-NP suspensions were 
characterized without any dilution by DLS using a 
Zetasizer Nano Series (Malvern, UK) by backscatter 
detection (λ = 630 nm, θ = 173°). Particle size (reported 
as Z-average of hydrodynamic diameter) was calculated 
as the average of three measurements of 10 runs for 10 s 
at 37°C. ζ-potential measurements through electropho-
retic mobility were carried out with a Zetasizer Nano 
analyzer (Malvern, UK) using disposable folded capil-
lary cells (DTS1061; Malvern, UK) at 25°C, suspend-
ing CaP-NPs in 10 mM HEPES buffer at pH 7.4. Three 
separate measurements (100 runs each) were collected 
in each case. Size and photon counts were also recorded 
continuously up to 300 min to evaluate the colloidal 
stability of CaP-NPs. Infrared spectra of freeze-dried 
samples were collected using a Nicolect 380 spectrom-
eter (Thermo Fisher Scientific, USA) with a resolution 
of 2 cm-1. 1 mg of sample was mixed with 150 mg of 
anhydrous potassium bromide (KBr). The mixture was 
pressed at 10 T pressure into a 7 mm diameter disc. A 
pure KBr disk was used as blank. Transmission electron 
microscopy (TEM) images and energy dispersive x-ray 
spectrum were collected using an FEI Tecnai F20 ST 
microscope operating at 200 kV. An aliquot of 20 μl 
of CaP-NP suspension was placed on carbon/formvar 
coated-copper grid for 5 min. The grid was then washed 
with ultrapure water and dried by manual blotting.
Cell line & primary cell culture
HL-1 cells were grown in Claycomb medium (Sigma-
Aldrich) supplemented with 10% FBS (Sigma-
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Aldrich), 1% penicillin-streptomycin (Pen-Strep 
10000 U/ml, Lonza), 1% ultraglutamine 1 (200 mM, 
Lonza) and 1 mM norepinephrine (Sigma-Aldrich) in 
gelatin/fibronectin precoated T75 flasks. After reach-
ing full confluence, cells were split 1:3 according to 
Dr Claycomb’s instructions [20]. Adult cardiomyocytes 
were isolated as previously described [21,22].
Trypan blue assay
HL-1 cells were seeded at 10 × 104 cells/well in pre-
coated 24-well plates (1 h, 37°C). All experiments were 
performed in triplicate. The day after seeding, HL-1 
cells were washed with PBS 1× and treated with dif-
ferent doses of CaP-NPs, ranging from 500 to 3.9 μg/
ml. After 24 h, HL-1 cells were collected with trypsin-
EDTA, resuspended in Claycomb complete medium 
and counted in a Trypan blue solution (Sigma-Aldrich). 
The percentage of dead cells over total number of cells 
was calculated.
Viability, cytotoxicity & caspase 3–7 assays
HL-1 cells or freshly isolated adult cardiomyocytes were 
seeded at 1 × 104 cells/well density in precoated 96-well 
plates (1 h, 37°C), and different doses of CaP-NPs were 
administered as specified in the text. All experiments 
were performed in triplicate. Viability, cytotoxicity and 
caspase-3/7 activities were measured using the ApoTox-
Glo triplex Assay (Promega™), according to the manu-
facturer’s instructions. Fluorescence and biolumines-
cence reactions were measured using a Synergy™ H4 
Hybrid Multi-Mode Microplate Reader (BioTek).
Inhibition of endocytosis
Clatrin inhibitor (PitStop2, abcam) and dynamin 
inhibitor (MiTMAB, abcam) were used at 1 μM. 
After 30 min incubation at 37°C, cells were treated 
with CaP-NPs for 24 h and processed as described in 
the text.
RNA isolation & quantification
Total RNA was extracted using PureZol Reagent 
(Biorad). Reverse transcription of RNA for miR-133, 
cel-miR-39 and U6 was performed using the miR-
CURYLNA™ Universal RT microRNA PCR Polyad-
enylation and cDNA synthesis kit (Exiqon). Quanti-
tative polymerase chain reaction was performed with 
microRNA LNA™ PCR primers (Exiqon) using the 
GoTaq® quantitative polymerase chain reaction Mas-
ter Mix (Promega). Relative expression was calculated 
using the ΔΔ(Ct) method.
Luciferase assay
The miR-133 luciferase sensor [22] was transfected 
into HEK–293 cells using Lipofectamine 2000 (Invi-
trogen), following the manufacturer’s protocol. After 
5 h, cell medium was changed and miRNA-loaded 
CaP-NPs added to the medium. 6 h post-treatment, 
cells were lysed and luciferase activity was measured as 
described by the manufacturer (Promega).
Confocal microscopy
HL-1 cells were seeded at 5.0 × 104 cells/well on VWR 
Micro cover slips coated with gelatin/fibronectin in 
complete Claycomb medium, and then incubated 
overnight at 37°C, 5% CO
2
. The following day, HL-1 
cells were treated with CaP-NP-FITC. 24 h post-treat-
ment, cultured cells were fixed using 4% paraformal-
dehyde at room temperature, followed by treatment 
in phosphate-buffered saline (PBS) containing 0.2% 
Triton X-100 for 5 min. After three washes with PBS, 
nuclei were counterstained with 4’,6-diamidino-2-phe-
nylindole, dihydrochloride, Life Technology for 5 min 
at room temperature. Fluorescent images were taken 
with a laser scanning confocal microscope (Olympus, 
FV1000/SIMS) [21].
Patch-Clamp recordings
Electrophysiological parameters of HL-1 cells and pri-
mary ventricular cardiomyocytes freshly isolated from 
adult mouse were measured using standard whole-
cell voltage-clamp and patch-clamp techniques. 
Experiments were conducted at room temperature. 
Patch pipette filling solution contained (in mmol/l): 
K-aspartate 120, NaCl 10, MgATP 3, CaCl
2
 1, EGTA 
10 and Hepes 5 (pH 7.2) with a free cytosolic Ca2+ 
concentration of 10–8 M. Analog signals were ampli-
fied, digitized (2.8 kHz) and filtered (1 kHz) with 
an MultiClamp 700B patch-clamp amplifier inte-
grated with an Axon’s Digidata 1440A AD/DA inter-
face and stored on a computer for off-line analysis 
using Clampfit v.10.3. Experimental protocols were 
controlled using Clampex software (version 10.3 
of pClamp, Axon Instruments). Pipette resistances 
ranged from 2 to 3 MOhm and pipette potentials were 
zeroed before cell contact. Liquid junction potential 
corrections calculated by the pClamp software were 
performed off-line after experiments. Preparations 
were superfused with Hank’s balanced salt solution 
(pH 7.40, buffered with 10 mmol/l Hepes) at 2–3 
ml/min at RT. Seal resistances were 2–10 GOhm. 
Rupturing the cell membrane in the patch resulted 
in access resistances of 2–10 MOhm. Clampex patch-
clamp amplifier allowed series resistances (70–90%) 
and whole cell capacitances electronic compensation. 
Action potentials (APs), resting membrane potential, 
input resistance (R
in
), membrane capacitance (C
m
) as 
well as sodium (I
Na
), calcium (I
Ca, L
) and net mem-
brane currents (NMCs) were measured in both single 
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HL-1 and adult ventricular cardiomyocytes in cur-
rent- and voltage-clamp modes. Resting membrane 
potential was measured in current-clamp modality, 
applying 10 s long current stimuli with the current 
value set to zero (pA = 0). C
m
 was measured utilizing a 
sinusoidal voltage stimulus and processing the result-
ing sinusoidal current using a phase-sensitive detector 
or ‘lock-in amplifier’ implemented either in Clampex 
hardware or software. R
in
 was calculated from voltage 
changes in response to 5 pA hyperpolarizing current 
steps from holding potentials. APs from which param-
eters as AP threshold (APTh), amplitude (APA), dura-
tion (APD
90
) and maximal upstroke velocity (dV/
dt
max
) were measured, were elicited with depolarizing 
current steps of 10 pA (3 ms) until threshold-APs 
were obtained. Threshold-Aps were after repeated 
10-times at a rate of 1 Hz and the 10th AP used for 
 measurements.
To study the effect of NPs on I
Na
, I
ca, L
 and NMCs 
of HL-1 cells and adult ventricular cardiomyocytes, 
standard step protocols and downward directed ramp 
were applied. In downward directed ramp protocols, 
the membrane was clamped from 50 to -110 mV over 
5000 ms (32 mV s-1 in order to inactivate voltage gated 
ion channels) from a holding potential of -80 mV for 
two-times at a rate of 0.1 Hz and I
Ca, L
 was blocked by 
addition of 0.2 mM nifedipine. To obtain sodium cur-
rent I–V relationships, 100 ms long voltage steps were 
applied, ranging from -90 to 65 mV from a holding 
potential of -80 mV at a rate of 0.33 Hz. Calcium I–V 
relations were obtained by measuring activated cur-
rents at different test potentials (300 ms, from -30 to 
75 mV at a rate of 0.25 Hz) from a holding potential 
of -40 mV. Steady-state activation curves were derived 
from each I/V relation and were described by fitting 
experimental points with the Boltzmann equation. To 
take into account the variations in cell size, current 
amplitude were normalized to C
m
 through all mea-
surements. In sodium current experiments, the patch 
pipette filling solution, and the Hank’s balanced salt 
solution were properly modified in order to bypass tech-
nical issues related to the capacity of the patch-clamp 
amplifier to track the fast sodium change in current 
and series resistance. Patch-clamp current and voltage 
traces were acquired at least at 5kHz,  depending on the 
protocol applied.
Cardiomyocyte contractility & Ca2+ transient 
recordings
Adult cardiomyocytes and HL-1 cells were loaded with 
1 μM Fura–2 acetoxymethyl (ThermoFischer Scien-
tific), field stimulated at 1.0 Hz and recorded using an 
IonOptix System (Milton, MA, USA), as previously 
described [21].
Statistics
Values are given as mean ± SD. Data were compared 
using the two-tailed Student t-test or Two-Way 
ANOVA and Bonferroni Test. Differences between 
data sets were considered significant at p < 0.05. 
All data were analyzed using Prism 6.0 software 
( GraphPad Software, Inc.).
Mice
All procedures on mice were performed according to 
institutional guidelines in compliance with national 
(D.L. N.26, 04/03/2014) and international law and 
policies (new directive 2010/63/EU). The proto-
col was approved by the Italian Ministry of Health. 
Special attention was paid to animal welfare and to 
minimize the number of animals used and their suffer-
ing. All experiments were performed on 10–week-old 
C57B6J male mice. Solutions were administered by 
retro-orbital administration as described elsewhere [23].
Results & discussion
Synthesis & characterization of CaP-NPs
Living organisms adopt complex biomineraliza-
tion processes to produce nanostructured materials 
endowed with high biocompatibility and stability [24]. 
These nanomaterials, when synthetically prepared 
with chemical–physical features very close to the bio-
genic ones, can therefore be ideal systems for biomedi-
cal applications, particularly as nanocarriers for drug 
delivery [25,26]. Synthetic biomimetic CaP-NPs, which 
resemble the main inorganic component of bones, 
teeth and also some pathological calcification, show 
high biocompatibility and pH-sensitive stability that 
facilitates the complete release of payload upon disso-
lution in biological acidic environments such as endo-
somes and lysosomes [27–29]. The complete dissolution 
of CaP in its ionic constituents (Ca2+ and PO
4
3-) pre-
vents undesirable NP accumulation in cells and tissues, 
a drawback often encountered with other inorganic 
and metallic NPs [30]. Based on this evidence, we gen-
erated CaP-NPs using a one-pot synthesis method, in 
which the biocompatible organic molecule citrate plays 
a relevant role in the mechanism of CaP crystallization. 
The benefit of citrate-based synthesis concerns the sta-
bilization of CaP-NPs at the early stage of crystalliza-
tion, which is due to the binding of citrate ions to the 
CaP surface. In fact, whereas a broad distribution in 
particle size is obtained when calcium and phosphate 
are mixed in solution in the absence of crystal-growth 
inhibitor, the adjustment of the citrate amount in 
solution allowed us to control morphology, crystallin-
ity and size of CaP-NPs [31]. Notably, a similar effect 
might occur in vivo in bones where citrate interacting 
at the surface of biogenic apatite nanocrystals (citrate 
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accounts for about 5.5 wt% of the total organic com-
ponent of bone tissue) can limit their further growth 
and renders the mineral surface more hydrophobic to 
interact with collagen [31,32].
DLS was used to monitor the effect of citrate on 
size and colloidal stability of CaP-NPs. Mean parti-
cle size (reported as Z-average) as well as count rate 
of the reaction medium were continuously recorded 
for 60 min. As shown in Figure 1A, incremental doses 
of sodium citrate (Na
3
Cit) significantly limited the 
growth of CaP-NPs, as evidenced by the slow increase 
in the mean particle size as a function of the crystal-
lization time. Moreover, higher Na
3
Cit concentrations 
also improved the colloidal stability of NPs as shown 
Figure 1B where the count rate of CaP-NPs prepared 
in the presence of 40 and 80 mM of Na
3
Cit remained 
nearly constant for 60 min compared with conditions 
at 0 and 20 mM Na
3
Cit. These results confirmed 
that no sedimentation occurred. Therefore, an initial 
Na
3
Cit concentration of 80 mM was selected for the 
further studies since it gave the best results in terms of 
size and colloidal stability of CaP-NPs.
The next step was to determine the most suitable 
time for crystallization through the evaluation of the 
chemical structure, size and surface charge of CaP-NPs. 
At determined crystallization times ranging from 5 to 
30 min, CaP-NPs were washed three-times by cen-
trifugation, freeze-dried and then analyzed by Fourier 
Transform Infrared spectroscopy (FT-IR) and DLS. 
Figure 1C displays the FT-IR spectra of CaP-NPs crys-
tallized at different times showing the typical bands of 
CaP compound (i.e., PO
4
3− vibration bands at 560−603 
[ν
4
], 962 [ν
1
] and 1000−1104 cm-1 [ν
3
] [33]). Moreover, 
since the synthesis was not carried out under inert gas, 
FT-IR spectra exhibited bands at 870 (ν
2
) and 1420 
cm−1 (ν
3
) assignable to CO
3
2- vibrations, which are 
characteristic for non-apatitic carbonates and B-type 
carbonate substitution (CO
3
 substitution for PO
4
3-), 
respectively [33]. The band at ca. 1600 cm-1, assignable 
to citrate (ν
as
OCO) [33], was also clearly visible in all 
samples. In addition, the narrowing of the bands at 
560–603 cm-1 revealed that amorphous CaP turned 
into a more crystalline state, following a time-depen-
dent process. The amorphous to crystalline transfor-
mation was quantitatively evaluated by means of the 
splitting factor (Table 1), a well-reported index for the 
evaluation of crystallinity degree of CaP-based materi-
als [34]. Additionally, while an increase in CaP-NP size 
was observed as a function of crystallization time, no 
significant variation was found for ζ-potential and poly-
dispersity index (PDI), which remained stable under all 
conditions (Table 1). In particular, ζ-potential values 
were negative, indicating that citrate covered the surface 
of NPs, thus providing a negative surface charge.
To remove any unreacted ions after 5 min of crys-
tallization, which gave the most promising results in 
terms of size of CaP-NPs for the further application 
as drug-delivery system, we applied a dialysis step 
that, in contrast to other purification procedures, such 
as centrifugation and freeze-drying or even purifica-
tion by desalting columns, prevents some irreversible 
agglomeration of adjacent particles. Thus, the removal 
of unreacted ions was assessed by measuring the con-
ductivity of the dialysis medium (outside the mem-
brane) as a function of time, which showed a plateau 
after 6 h of treatment (Supplementary Figure 1A). This 
conductivity plateau indicated that the equilibrium 
of ionic exchange from the reaction medium to the 
dialysis medium was reached and a large majority of 
the unreacted ions were removed. Z-average, PDI and 
ζ-potential of CaP-NPs after 6 h of dialysis were 129 
± 2 nm, 0.18 ± 0.10 and -31.5 ± 1.5 mV, respectively. 
These results indicated that dialysis, in contrast to the 
washing step via centrifugation (data not shown), dras-
tically decreased the mean size of CaP-NPs as well as 
narrowed size distribution (low PDI) while preserving 
a constant negative ζ-potential, which is a fundamen-
tal prerequisite for the use of nanocarriers in excitable 
cardiac cells [19]. In addition, the stability of CaP-NPs 
after washing by dialysis was evaluated by DLS mea-
surements for 300 min (Supplementary Figure 1B). A 
constant particle size as well as mean count rate dem-
onstrated that neither aggregation nor sedimentation 
occurred.
Finally, morphological analysis by TEM revealed 
CaP-NPs as round shape particles of about 20–50 nm 
in diameter (Figure 1D). The smaller size determined 
by TEM in comparison to that quantified by DLS is 
consistent with the ability to analyze the dried solid 
material diameter via the TEM technique in contrast 
to DLS, which gives the hydrodynamic size distribu-
tion in suspension of solid particle, organic layers and 
surrounding liquid. Moreover, selected area electron 
diffraction (SAED) pattern (Figure 1D, inset) con-
firmed their amorphous nature (i.e., presence of dif-
fuse rings rather than spots) while energy dispersive 
X-ray analysis (Supplementary Figure 1C) corroborated 
their chemical composition (i.e., presence of Ca and 
P together with C, O and Cu from the cooper grid 
coated with carbon/formvar support film).
CaP-NP biocompatibility & cellular 
internalization
Our next objective was to test the biocompatibility 
of optimized CaP-NPs by subjecting HL-1 cardiac 
cells to incremental doses of CaP-NPs (0–500 μg/
ml). As demonstrated by Trypan blue exclusion assay 
(Figure 2A), HL-1 cells largely tolerated an acute 
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Figure 1. Chemical–physical and morphological characterization of CaP-NPs.(A) Mean particle size (Z-average) 
and (B) count rate (counts) as a function of time, analyzed by DLS during CaP-NPs crystallization in the absence 
(0 mM) and presence of Na3Cit at different concentrations. (C) FT-IR spectra of CaP-NPs prepared in the presence 
of Na3Cit (80 mM) at different crystallization times (i.e., 5, 10, 20 and 60 min). (D) TEM image of CaP-NPs. 
Inset: corresponding SAED pattern. 
DLS: Dynamic light scattering; SAED: Selected area electron diffraction; TEM: Transmission electron microscopy.
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administration of CaP-NPs, showing an increase in 
mortality rate only at higher doses (>125 μg/ml) and 
24 h postadministration. This finding was further 
supported by a viability, cytotoxicity and caspase 3–7 
assay, which showed a significant increased levels of 
apoptotic activity only with chronic administration 
of higher concentrations (≥250 μg/ml) of CaP-NPs 
(Figure 2B & Supplementary Figure 2). We tested bio-
Table 1. Splitting factor, Z-average, polydispersity index and ζ-potential of freeze-dried CaP-NPs 
(synthesized in the presence of 40 mM of Na3Cit) as a function of crystallization time.
Crystallization time 
(min)
SF† Z-average (nm) PDI ζ-potential (mV)
5 No calculable 1175 ± 110 0.55 ± 0.03 -26.9 ± 0.6
10 1.76 1656 ± 408 0.52 ± 0.03 -25.9 ± 0.9
20 2.16 2405 ± 402 0.38 ± 0.02 -26.1 ± 0.7
60 2.25 3376 ± 851 0.44 ± 0.02 -30.4 ± 1.3
†Calculated from FT-IR spectra (SF: measure consists on sum of the heights of the stretching of phosphates peaks at 603 and 560 cm−1 and 
divided by the height of the valley between them at ∼588 cm−1; all heights were measured above a baseline drawn from approximately 
780–495 cm−1).
PDI: Polydispersity index; SF: Splitting factor.
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Figure 2. Biocompatibility of HL-1 cardiac cells to 
CaP-NPs. (A) Cell toxicity as measured by Trypan blue 
exclusion assay in HL-1 cells treated as indicated. (B) 
Apoptosis detection via activated caspase 3 and 7 assay 
in HL-1 cells treated with increasing concentration of 
CaP-NPs. (C) Cellular internalization of FITC-conjugated 
CaP-NPs (green); nucleus (blue).§§§p < 0.001 compared 
with conditions of no CaP-NP treatment (NT) using 
Two-way Anova followed by Dunnet’s multiple 
comparison test. 
*p < 0.05; **p < 0.005; ***p < 0.001 calculated for 
each CaP-NP dose using Two-way Anova followed by a 
Bonferroni’s test.
0
20
40
CaP-NP (µg/ml)
N
o
t 
vi
ab
le
 c
el
ls
 (
%
)
3.8 7.80 15.6 31.2 62.5 125 500
60
250
** **
§§§
***
§§§
***
§§§
***
0.0
0.5
1.0
CaP-NP (µg/ml)
C
as
p
as
e-
3 
7A
ct
iv
it
y 
(R
L
U
)
3.8 7.80 15.6 31.2 62.5 125 500
1.5
2.0
250
No inh.
Clathrin inh. (1 uM)
Dynamin inh. (1 uM)
*
*
future science group
Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs    Research Article
compatibility also on adult cardiomyocytes subjected 
to the same dose/responses for CaP-NPs and no differ-
ences were observed (Supplementary Figure 3). Based 
on these results, a concentration of 20 μg/ml was 
 chosen for the subsequent studies.
Cellular internalization was evaluated by exposing 
HL-1 cells to CaP-NPs conjugated to the fluorescein 
isothiocyanate (FITC). Confocal microscopy revealed 
distinct vesicular compartmentation, confirming 
the internalization of CaP-NP-FITC (Figure 2C). To 
determine whether the internalization was due to 
active mechanisms of endocytosis, specific inhibitors 
of clathrin and dynamin, which are involved in the 
initial processes of endocytosis and invagination from 
the plasma membrane, were used. Following pretreat-
ment with these inhibitors, HL-1 cells were exposed to 
increasing concentrations of CaP-NPs, and a Trypan 
blue exclusion assay was performed as described above. 
In accordance with our previous studies of negative-
charged NPs [35], inhibition of dynamin- and clathrin-
mediated endocytosis significantly reduced cellular 
toxicity at all doses of CaP-NPs, suggesting that inter-
nalization occurs via conventional clathrin- and dyna-
min-mediated endocytosis (Figure 2A). Altogether, the 
above findings demonstrate that CaP-NPs efficiently 
internalize into the cytoplasmic intracellular space of 
cardiac cells without inducing toxicity or apoptosis.
Effects of CaP-NPs on cardiomyocyte function
One of the main concerns in using calcium-based NPs 
is their potential interference with functional properties 
of excitable and contractile cells, such as cardiomyo-
cytes. Thus, to evaluate any potential effect that CaP-
NPs might have on cellular physiological properties 
and functions, a complete electrophysiological evalua-
tion was performed on HL-1 cells as well as primary 
ventricular cardiomyocytes freshly isolated from adult 
mouse. To this end, HL-1 and adult cardiomyocytes 
were exposed to 20 μg/ml of CaP-NPs for 24 h (chronic 
stimulation) or 5 h (acute stimulation), respectively. As 
shown in Supplementary Figure 4, results from voltage-
clamp experiments showed no effect of CaP-NPs on any 
of the typical characteristics of cell excitability, includ-
ing membrane potential (V
m
), membrane capacitance 
(C
m
), membrane resistance (R
m
), threshold of the AP, 
AP amplitude (APA), maximum speed of ascent of 
the AP (dV/dt
max
) and AP duration (APD). Similarly, 
analyses of the main ionic currents underlying the typi-
cal cardiac cell AP (sodium, calcium and potassium 
currents measured by appropriate steps and ramp pro-
tocols) showed no significant differences between con-
trols and treated cells under both chronic (Figure 3) and 
acute conditions (Figure 4). Ramps protocols shown in 
Figures 3A & 4A, B were used to measure NMCs which 
represent the activation of at least three time  independent 
or slowly  activating K+ currents (I
K1
, I
Kr
 and I
Ks
) [36].
Finally, we evaluated adult cardiomyocyte contrac-
tility and intracellular calcium transients, a process 
associated with the excitation–contraction coupling of 
cardiac cells [37]. As shown in Supplementary Table 1, 
no significant alterations were found between treated 
and untreated conditions, further supporting the 
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Figure 3. Voltage–current relationship (I–V curve) in HL-1 cells exposed to CaP-NPs. (A) Top row. Net membrane 
current I–V curves for control (left, black) and exposed (right, gray) HL-1 cells. Bottom row. Superimposition 
of the two curves (left) and net membrane current difference curve (right). (B) Sodium current traces for both 
conditions. Bottom. I–V curve for sodium currents and voltage dependency of sodium channel activation (g/gmax, 
right) for control (black) and exposed (gray) HL-1 cells.
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Figure 5. CaP-NP-miR assembly. (A) Schematic illustration of the formation mechanism of CaP-NP-miRs. (B) TEM 
images of CaP-NP-miRs; inset: corresponding SAED pattern. 
SAED: Selected area electron diffraction.
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evidence that administration of CaP-NPs does not 
alter cellular functional properties of cardiac cells. 
Similarly, no significant alterations in intracellular 
calcium transients were found in HL-1 treated cells 
(Supplementary Table 2).
Taken together, these findings indicate good bio-
compatibility of CaP-NPs for cardiac cells, suggesting 
their potential use as drug nanocarriers for CVDs.
CaP-NPs encapsulate & deliver miRNAs into 
cardiac cells
We next asked whether CaP-NPs can efficiently bind 
synthetic compounds (e.g., miRNAs) and thus poten-
tially be used as effective nanocarriers for intracellu-
lar drug delivery. For this purpose, different amounts 
of synthetic unmodified and unprotected miRNA 
duplexes (ranging from 1 to 10 μg ml-1) were added 
to the reaction medium during the one-pot CaP-NP 
synthesis protocol described above. DLS analysis 
revealed that the size of CaP-NP-miRNAs (CaP-NP-
miRs) increased as a function of miRNA amount, 
while PDI values and surface charge remained close to 
those of miRNA-free CaP-NPs (Table 2). The increase 
in size could be associated with an effective interaction 
of miRNAs with CaP-NPs, while unaltered surface 
charge and PDI indicated that also in this case citrate 
homogenously covered the NP surface. A scheme of 
a possible formation mechanism of CaP-NP-miRs is 
shown in Figure 5A. TEM analysis of CaP-NP-miRs 
(Figure 5B) revealed round shape NPs of approximately 
20–30 nm in diameter similar to miRNA-free CaP-
NPs. In addition, the presence of diffuse rings in the 
SAED pattern of CaP-NP-miRs (Figure 5B, inset) 
validated their amorphous nature, suggesting that the 
presence of miRNA under these experimental condi-
tions did not induce or accelerate the crystallization 
mechanism of CaP-NPs.
To evaluate the efficiency of miRNA delivery, we 
exposed HL-1 cells to CaP-NP-miRs (carrying either 
the muscle-enriched miR-133 or the not-mammalian C. 
elegans cel-miR-39–3p) and measured intracellular lev-
els of miRNAs at different time points post-treatment. 
For these experiments CaP-NP-miRs were prepared 
using the maximum initial concentration of miRNA. 
As shown in Figure 6A & B, qRT-PCR analyses of total 
RNA revealed an effective time-dependent increase in 
the levels of intracellular delivered miRNA, confirming 
the effective encapsulation of both miRNAs into CaP-
NPs as well as their cellular uptake. A similar result of 
CaP-NP-mediated uptake of miRNA was confirmed in 
adult cardiomyocytes (Supplementary Figure 5). Addi-
tionally, a cell-based luciferase assay confirmed that the 
administered CaP-NP-miR-133 efficiently repressed an 
miR-133-specific target [22] (Figure 6C).
Altogether, our findings provide evidence that func-
tionalized CaP-NPs possess an intrinsic ability to carry 
functional miRNAs into cardiac cells.
Uptake of CaP-NP-miRs in vivo
As a final step, we evaluated as a proof of concept the 
in vivo efficiency of CaP-NPs as drug-delivery sys-
tem. In particular, CaP-NP-miRs (complexed with 
the exogenous cel-miR-39–3p) were administered to 
10-week-old mice by retro-orbital injection (once a 
day for three consecutive days), whereafter qRT-PCR 
analyses were performed on total RNA isolated from 
various tissues. As shown in Figure 7, a significant 
accumulation of cel-miR-39–3p was found in the left 
ventricle as well as liver, spleen and kidney, whereas no 
signals were detected in brain, likely due to the high 
filtering efficiency of the hematic–encephalic barrier. 
These results demonstrate the capacity of our formula-
tion for intracellular drug-delivery in vivo.
Discussion
In this report, a novel and safe drug-delivery system 
based on bioinspired negatively charged CaP-NPs was 
generated. To the best of our knowledge this repre-
sents the first cross-domain study that, ranging from 
functional chemistry to molecular and cellular cardiac 
physiology, provides important advances in the field of 
cardiovascular nanomedicine.
When selecting suitable nanocarriers for drug deliv-
ery, several concerns hindering the potential clinical 
translation of NPs (i.e., the biodegradability of the 
materials, the toxicity of degradation byproducts, the 
Table 2. Z-average, polydispersity index and ζ-potential of CaP-NP-miRs, as a function of miRNA 
concentration added during nanoparticle synthesis.
miRNA (μg ml−1) Z-average (nm) PDI ζ-potential (mV)
0 129 ± 2 0.18 ± 0.10 -31.5 ± 1.5
1 156 ± 6 0.23 ± 0.10 -29.6 ± 2.6
5 199 ± 11 0.20 ± 0.05 -36.6 ± 1.6
10 225 ± 6 0.17 ± 0.05 -32.1 ± 3.0
PDI: Polydispersity index.
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Figure 6. In vitro CaP-NP delivery into a cardiac cell 
line. (A & B) qRT-PCR on HL-1 cells treated for 6 and 
12 h with CaP-NP-miRs loaded with miR-133a (up) 
and cel-miR-39–3p (down). (C) Luciferase reporter 
activity measured on HEK–293 cells transfected with a 
luciferase sensor and treated for 6 h with CaP-NP-miR 
carrying miR-133.
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toxic structural features of NPs and protection of the 
payload) need to be taken into account [38]. CaP, a syn-
thetic carrier resembling biogenic compounds, has ideal 
properties of biocompatibility, bioresorbability and 
biodegradability because of its structural and chemical 
similarity with the mineral component of bones and 
teeth [39]. Furthermore, CaP-based carriers provide 
the further improvement of  nonimmunogenicity and 
minimal or absent toxicity [27,28].
An additional advantage of CaP-NPs is related to 
the fact that at acidic pH, as found in endosomes and 
lysosomes after cellular intake, these nanocarriers rap-
idly dissolve into their ionic constituents facilitating 
the release of their cargo into the cytoplasm without 
any residual accumulation in cells and tissues, a critical 
drawback often encountered with other inorganic and 
metallic NPs [40].
The concept of preparing CaP-NPs for the encap-
sulation of RNA or DNA molecules, as opposed to 
surface decoration or adsorption where the therapeu-
tic agent is not protected from the biological environ-
ment, is not new per se [41]. This strategy requires the 
presence of a capping agent to prevent the formation of 
large polydisperse and polymorphous micro-sized par-
ticles [42], and a variety of capping agents mainly based 
on synthetic polymers such as polyethylene glycol [43], 
poly(methacrylic acid) [44] or polyethylenimine [45] have 
been already used to stabilize CaP particles for gene 
delivery. However, synthetic polymers such as polyeth-
ylenimine are cytotoxic and not suitable for the in vivo 
delivery of nucleic acids [46,47]. Therefore, the identifi-
cation of alternative and more ‘biofriendly’ stabilizing 
agents is an effective need. In this study, we have modi-
fied the conventional synthesis of CaP-NPs by includ-
ing Na
3
Cit in the synthesis process providing: improve-
ment in the control of CaP growth tailoring the final 
dimensions, enhancement of colloidal stability and 
negative surface charge. In addition, and in contrast 
to previous synthetic polymers, we employed citrate, 
which is a fully biocompatible organic molecule pres-
ent in several biological environments such as the bone 
apatite surface [48]. Finally, by applying a final step of 
dialysis, we drastically reduced the mean size of CaP-
NPs and increased their stability. In the last years, other 
authors employed citrate as stabilizing agent to prepare 
effective CaP-NPs as nonviral vectors for the delivery 
of nucleic acids [49–51]. However, here, differently from 
the previous works, miRNA was included during the 
synthesis of CaP-NP assisted by citrate, with the aim to 
encapsulate the active agent into the NPs as opposed to 
surface decoration for the reasons described above.
We recently introduced the concept that excitable 
cells are prone to (electro)toxicity. In fact, by measur-
ing passive and active electrophysiologic properties of 
cardiomyocytes subjected to charged synthetic NPs, we 
found that polarized cells have a selective compatibility 
for negatively charged NPs [35,52]. In agreement with 
these results, the negatively charged CaP-NPs gener-
ated in this study did not affect any of the functional 
parameters we measured in cardiac cells. In particular, 
we did not observe any changes in passive membrane 
properties, known to be a signature of arrhythmo-
genesis [52]. The relevance of these results points to a 
www.futuremedicine.com 903
Figure 7. In vivo administration of CaP-NP-miRs. 
qRT-PCR performed on total RNA from various organs 
following 3 days of retro-orbital injection of CaP-NP-
miRs carrying cel-miR-39–3p.
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promising employment of CaP-NPs for cardiac-related 
applications in vivo.
The functionalization of CaP-NPs with a nega-
tively charged surface is beneficial also for crossing the 
lipid bilayer of the cell membrane. Our results showed 
that internalization of CaP-NPs occurs via clathrin- 
mediated active endocytosis, which is in line with 
our previous study [35]. However, in a recent study it 
was also shown that CaP internalization in Hela and 
COS7 cells follows the caveolae-mediated path [53]. 
While this process is indeed effective in those cells [53], 
the caveolae-mediated internalization is most likely not 
occurring in excitable cells such as cardiomyocytes and 
HL-1 where on the other hand caveolae and lipid-rafts 
constitute well-organized microdomains deputed for 
the thorough regulation of cardiac ion channel func-
tion [54]. This is in line with our data showing that 
administration of CaP-NPs to cardiac cells does not 
induce any alteration in cell membrane capacitance 
(Supplementary Figure 4C), an index of absence of 
pinocytosis or caveosome endocytosis of lipid rafts [55].
Nowadays, a great effort is made toward the identifi-
cation of nanoformulations capable of specific delivery 
of small therapeutic agents (i.e., nucleic acids or pep-
tides) to tissues and cells [56]. To meet this demand, 
we have used an innovative approach for the genera-
tion of CaP-NPs, which can easily and cost-effectively 
bind miRNAs, small nucleic acids with enormous 
therapeutic potentials. In particular, we showed that 
CaP-NP-miRs are efficient for in vitro and in vivo 
miRNA delivery and able to target polarized tissues, 
such as the heart, although further improvements are 
still required to overcome limitations associated with 
cell-type specific targeting. In addition, the approach 
of encapsulating miRNAs into CaP-NPs bypasses 
potential problems occurring with the majority of 
current miRNA-delivery systems. In fact, in contrast 
to surface decoration or adsorption approaches, this 
approach increases the stability and functionality of 
miRNAs.
Conclusion
In summary, our study provides the proof of concept 
for an innovative, safe and efficient CaP based drug-
delivery system in which the homogeneity of the nano-
complex can be controlled by adding citrate during the 
crystallization process. The resulting CaP-NPs were 
biocompatible with the viability and electrophysiology 
of a cardiac cell line and primary cardiomyocytes. In 
addition, CaP-NPs were demonstrated to carry and 
efficiently release miRNAs both in vitro and in vivo. 
All together, we envisage that the current study will 
open up new avenues for the potential application of 
CaP-NPs in the context of cardiac nanomedicine.
Future perspective
In this study we developed bioinspired and negatively 
surface charged NPs, which are able to encapsulate and 
carry miRNAs into cardiac cells both in vitro and in vivo. 
In the emerging field of nanomedicine, controlling the 
negative charge of the nanocarriers in terms of negative 
surface potential can be beneficial in facilitating the tar-
geting of hyperpolarized and excitable organs. Further 
prospective studies, together with a long-term in vivo tox-
icity evaluation and comparison with other delivery sys-
tems, will provide evidence-based data to support the use 
of this nanoapproach for the treatment of CVD. Addi-
tionally, key investigations in support of effective human 
translatability and personalized medicine applications 
would require experimentations in cultured induced plu-
ripotent stem cells derived cardiomyocytes from cardiac 
pathologies. This will contribute with better understand-
ing of doses, toxicity and the beneficial miRNA effect 
together with the possibility to carry other drugs, pep-
tides or siRNAs to the diseased heart. Altogether, this 
will open up the potential use of bioinspired and surface 
charged NPs for future therapeutic approaches.
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Executive summary
Objective
•	 To develop biocompatible and bioresorbable negatively charged calcium-phosphate nanoparticles (CaP-NPs) 
as an innovative therapeutic system for the delivery of bioactive molecules to the heart.
Experimental setup
•	 CaP-NPs were synthetized via a straightforward one-pot biomineralization-inspired protocol employing citrate 
as a stabilizing agent and regulator of crystal growth.
•	 CaP-NPs were administered to cardiac cells in vitro and the effects of treatments were assessed.
•	 CaP-NPs were delivered in vivo.
Results
•	 CaP-NPs efficiently internalized into cardiomyocytes.
•	 CaP-NPs do not promote cell toxicity nor interfere with any functional properties of cardiomyocytes.
•	 CaP-NPs successfully encapsulated synthetic microRNAs, which were efficiently delivered into cardiac tissue 
in vitro and in vivo.
Conclusion
•	 CaP-NPs are a safe and efficient drug-delivery system for potential therapeutic treatments of polarized cells 
such as cardiomyocytes.
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